Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.

Advertisement

Related Content

Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA
Gilead’s Quad Makes It Through FDA Panel Review Despite Renal Safety Concerns
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel